Woodcock's future retirement will mark new era for FDA's drug center

10/10/2013 | Reuters

Some drugmakers are worried that the pace of drug approvals could slow after Janet Woodcock retires as director of the FDA's Center for Drug Evaluation and Research, according to this article. Woodcock is at least a year away from leaving that role. FDA divestment rules and other obstacles can make it hard to find a successor, she said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC